The theoretical impact of AI-based quality evaluation of short-video health information on public cognition and treatment adherence: a case study of denosumab combined with PD-1/PD-L1 therapy for lung cancer bone metastasis

人工智能辅助短视频健康信息质量评价对公众认知和治疗依从性的理论影响:以地诺单抗联合PD-1/PD-L1疗法治疗肺癌骨转移为例

阅读:1

Abstract

BACKGROUND: Bone metastasis occurs in 30-40% of patients with advanced non-small cell lung cancer (NSCLC), and denosumab combined with PD-1/PD-L1 inhibitors has emerged as a promising treatment strategy. However, the "algorithmic echo chamber" effect on short-video platforms may distort patient cognition and treatment decision-making. METHODS: A cross-sectional study was conducted using a custom-developed web crawler to collect 1,369 videos from Bilibili, Douyin, and Xiaohongshu. A total of 402 videos were included after a three-tier keyword filtering process. An AI-based evaluation system built upon the doubao-seed-1.6 model was established, integrating three international standards-Global Quality Score (GQS), Journal of the American Medical Association (JAMA) benchmark criteria, and the modified DISCERN tool-to assess multidimensional information quality. Kruskal-Wallis tests and Spearman correlation analyses were performed to explore inter-platform differences and the relationship between information quality and user engagement metrics. RESULTS: Overall video quality was substantially below professional medical standards: the mean GQS was 2.84 ± 1.06 (56.8% of the full score), JAMA was 0.34 ± 0.57 (8.5%), and modified DISCERN was 1.55 ± 0.69 (31.0%). Significant quality differences were observed across platforms (p < 0.001, Cohen's d = 0.6-0.8): Douyin ranked highest, followed by Xiaohongshu, with Bilibili lowest. Correlation between user engagement and content quality was extremely weak (R(2) = 0.004, r = 0.062), indicating substantial decoupling-high engagement did not equate to high-quality content. Medical professionals accounted for only 25.6% of content creators, while patient-generated content reached 52.2%. Evidence-based treatment information comprised merely 20.0-26.7%, whereas misleading or inaccurate claims accounted for 6.7-13.3%. CONCLUSION: From a behavioral and cognitive perspective, the low quality of immune-oncology information on short-video platforms, coupled with algorithm-driven amplification of high-engagement but low-quality content, may exacerbate cognitive bias, potentially increasing clinical safety risks such as insufficient hypocalcemia monitoring and inadequate MRONJ prevention. Establishing a professional governance and oversight system is urgently required.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。